Acura Pharmaceuticals Announces First Quarter 2016

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Acura Pharmaceuticals Announces First Quarter 2016 Financial Results

PALATINE, IL --(Marketwired - May 02, 2016) - Acura Pharmaceuticals, Inc. ( NASDAQ : ACUR ), a specialty pharmaceutical company innovating abuse deterrent drugs, announced today financial results for the first quarter ended March 31, 2016.

The Company reported net loss of $3.4 million for the first quarter 2016 or $0.28 per diluted share, compared to net income of $1.2 million or $0.13 per diluted share for the same period in 2015. Revenues for the quarter were $0.2 million compared to $5.4 million in the first quarter of 2015 which included the $5.0 million payment arising from licensing Oxaydo to Egalet Corporation entities.

Research and development expenses associated with product candidates utilizing the Company's LIMITX™, AVERSION® and IMPEDE® Technologies were $1.0 million in each of the first quarters 2016 and 2015. Selling, marketing, general and administrative expenses were $2.2 million in first quarter 2016 compared to $2.3 million in the first quarter 2015. Selling expenses primarily consisted of advertising and marketing activities for NEXAFED® and NEXAFED® SINUS.

As of April 30, 2016, our cash, cash equivalents and marketable securities less our compensating balance requirement of $2.5 million was $7.7 million, and we had $7.4 million in term debt financing.

Conference Call Information

Acura Pharmaceuticals is, Inc. will host a conference call on Tuesday, May 3, 2016 at 8:30 a.m. EDT to discuss the results.

To participate in the live conference call, please dial 888-339-3513 (U.S. and Canada) five to ten minutes prior to the start of the call. The participant passcode is 6043967. A digital replay of the call will be available beginning May 3, 2016 and ending on May 24, 2016 on the company's website, and by dialing 888-203-1112 (U.S. and Canada). The replay participant code is 6043967.

About Acura Pharmaceuticals

Acura Pharmaceuticals is a specialty pharmaceutical company engaged in the research, development and commercialization of product candidates intended to address medication abuse and misuse, utilizing its proprietary LIMITX™, AVERSION® and IMPEDE® Technologies. LIMITX contains ingredients that are intended to reduce or limit the rate or extent of opioid release when multiple tablets are ingested. AVERSION contains polymers that cause the drug to gel when dissolved; it also contains compounds that irritate the nasal passages if the product is snorted. IMPEDE is designed to disrupt the processing of pseudoephedrine from tablets into methamphetamine.

OXAYDO® (oxycodone HCl immediate-release tablets) which incorporates the AVERSION Technology, is FDA approved and marketed in the U.S. by our partner Egalet Corporation. 

Acura markets NEXAFED® and NEXAFED® Sinus, which are pseudoephedrine containing products that utilize the IMPEDE Technology.

Forward-Looking Statements

Certain statements in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Forward-looking statements may include, but are not limited to:

  • our ability to fund or obtain funding for our continuing operations, including the development of our products utilizing our LIMITX™ and IMPEDE® technologies;
  • the expected results of clinical studies relating to LTX-04, the date by which such study results will be available and whether LTX-04 will ultimately receive FDA approval;
  • whether LIMITX will retard the release of opioid active ingredients as dose levels increase;
  • whether we will be able to reformulate LTX-04 to provide an efficacious level of drug when one or two tablets are taken;
  • whether our LIMITX technology can be expanded into extended-release formulations;
  • our ability to fund or obtain funding for our continuing operations, including the development of our products utilizing our LIMITX and IMPEDE technologies;
  • our and our licensee's ability to successfully launch and commercialize our products and technologies, including OXAYDO® Tablets and our NEXAFED® products;
  • the pricing and price discounting that may be offered by Egalet for OXAYDO;
  • whether we can successfully develop a product under our agreement with Bayer;
  • the results of our development of our LIMITX technology;
  • our and our licensee's ability to obtain necessary regulatory approvals and commercialize products utilizing our technologies;
  • the market acceptance of, timing of commercial launch and competitive environment for any of our products;
  • the willingness of pharmacies to stock our NEXAFED products;
  • expectations regarding potential market share for our products;
  • our ability to develop and enter into additional license agreements for our product candidates using our technologies;
  • our exposure to product liability and other lawsuits in connection with the commercialization of our products;
  • the increasing cost of insurance and the availability of product liability insurance coverage;
  • the ability to avoid infringement of patents, trademarks and other proprietary rights of third parties;
  • the ability of our patents to protect our products from generic competition and our ability to protect and enforce our patent rights in any paragraph IV patent infringement litigation;
  • the ability to fulfill the FDA requirements for approving our product candidates for commercial manufacturing and distribution in the United States, including, without limitation, the adequacy of the results of the laboratory and clinical studies completed to date, the results of laboratory and clinical studies we may complete in the future to support FDA approval of our product candidates and the sufficiency of our development process to meet over-the-counter ("OTC") Monograph standards, as applicable;
  • the adequacy of the development program for our product candidates, including whether additional clinical studies will be required to support FDA approval of our product candidates;
  • changes in regulatory requirements;
  • adverse safety findings relating to our commercialized products or product candidates in development;
  • whether the FDA will agree with our analysis of our clinical and laboratory studies;
  • whether further studies of our product candidates will be required to support FDA approval;
  • whether or when we are able to obtain FDA approval of labeling for our product candidates for the proposed indications and will be able to promote the features of our abuse discouraging technologies; and
  • whether OXAYDO or our AVERSION® and LIMITX product candidates will ultimately deter abuse in commercial settings and whether our NEXAFED products and Impede technology product candidates will disrupt the processing of pseudoephedrine into methamphetamine.

In some cases, you can identify forward- looking statements by terms such as "may," "will", "should," "could," "would," "expects," "plans," "anticipates," "believes," "estimates," "indicates", "projects," predicts," "potential" and similar expressions intended to identify forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. We discuss many of these risks in greater detail in our filings with the Securities and Exchange Commission.

 
ACURA PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands)
    (unaudited)   (audited)
    March 31,   December 31,
    2016   2015
Current assets   $ 11,632   $ 14,135
Property, plant and equipment, net     1,028     1,013
Other assets     1,761     1,813
  Total assets   $ 14,421   $ 16,961
             
Other current liabilities   $ 1,853   $ 924
Debt - current     2,575     2,320
Debt - non-current portion, net of discount of $167 and $193, and debt issuance costs of $83 and $97     4,806     5,430
Accrued interest - non-current portion     433     387
Stockholders' equity     4,754     7,900
  Total liabilities and stockholders' equity   $ 14,421   $ 16,961
               
 
ACURA PHARMACEUTICALS, INC.
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
(Unaudited; in thousands, except per share amounts)
    (unaudited)
    Three Months Ended March 31,
    2016   2015
Revenues:        
  License fee revenue   $ -     $ 5,000  
  Collaboration revenue     100       -  
  Royalty revenue     17       -  
  Product sales, net     107       357  
    Total revenues, net     224       5,357  
Operating expenses:                
  Cost of sales (excluding inventory write-down)     102       324  
  Inventory write-down     -       260  
  Research and development     1,014       964  
  Selling, marketing, general and administrative     2,246       2,297  
    Total operating expenses     3,362       3,845  
    Operating (loss) income     (3,138 )     1,512  
Non-operating income (expense):                
  Investment income     27       35  
  Interest expense     (249 )     (308 )
  Other expense     (24 )     -  
    Total other expense, net     (246 )     (273 )
    (Loss) income before income taxes     (3,384 )     1,239  
  Provision for income taxes     -       -  
    Net (loss) income   $ (3,384 )   $ 1,239  
Other comprehensive income:                
  Unrealized gains on securities     70       31  
    Comprehensive (loss) income   $ (3,314 )   $ 1,270  
                 
                 
(Loss) income per share:                
  Basic   $ (0.28 )   $ 0.13  
  Diluted   $ (0.28 )   $ 0.13  
Weighted average shares outstanding:                
  Basic     11,968       9,793  
  Diluted     11,968       9,869  
                 

Contact: for Acura Investor Relations Email contact (847) 705-7709 Renmark Financial Communications Inc. Robert Thaemlitz Email contact (416) 644-2020 or (514) 939-3989 www.renmarkfinancial.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

GALC Launches Tender Offer on 2027 Notes Amid Debt Play

Updated Category News Views 70

Aviation Leasing Giant's Strategic Financial Move Well folks, we're staring down the barrel of a financial maneuver by Global Aircraft Leasing Co., Ltd. (GALC) that’s not just another day at the office. They've kicked off a cash tender offer for their 8.750% Senior Secured Notes due 2027, aiming to sweep up any and all outstanding ones. That's $932 million in principle...

Continue Reading
Cracking Life Insurance Needs: John Dorsa's Insights

Updated Category News Views 119

Life Insurance: A Necessary Puzzle Life’s uncertainties have a way of putting a wrench in our plans, and nothing screams uncertainty like figuring out life insurance. But fret not! HelloNation’s got insights on this financial maze, and they’ve roped in insurance pro John Dorsa from Ridgeland to help out. Calculating Coverage Needs Forget the one-size-fits-all...

Continue Reading
Choate's Expands to New Mid-South Markets

Updated Category News Views 155

Family Traditions Drive Choate's Growth Back in the day, you might've thought the family-run businesses were a dying breed, right? Not in the case of Choate's Air Conditioning, Heating, Plumbing & Electrical. These folks aren't just holding the fort; they're storming new territories across the Mid-South like they've got something to prove—or maybe just something to...

Continue Reading
Zettia R. Barnes: Charting a Path in Home Healthcare

Updated Category News Views 146

The Lifeline of Home Healthcare in DeSoto You know, it ain't every day that someone like Zettia R. Barnes steps up in the realm of home healthcare and makes a mark that genuinely sticks. From rubbing shoulders with patients to steering a whole dang organization like Angels of Hands Home Health Agency Corp., she's got her hands full—and frankly, it’s folks like her who...

Continue Reading
Texxon Faces Revenue Slide Amid Strategic Shifts

Updated Category News Views 108

Texxon's Strategic Transitions and Financial Headaches Texxon Holding Limited (NASDAQ:NPT) just laid their cards on the table, unveiling a mixed bag in their fiscal year 2026 results. As the world's chemical and plastics scene faces winds of change, Texxon buckled down and tried to steer the ship clear from the rocks. It's a balancing act juggling market headwinds, a new...

Continue Reading
Québecor Makes Its Move: Eye on TELUS Amid Telecom Shakeup

Updated Category News Views 142

The Offer That Shocked the Telecom Markets Just when you think you’ve figured out the lay of the land, someone throws a curveball. Québecor’s decision to take a run at TELUS is shaking up Canada’s telecom scene big time. This isn’t just another M&A whisper; it’s a roaring freight train of a proposal valued at a whopping $31 billion. And TELUS, not just sitting...

Continue Reading
Paris Baguette Expands U.S. Presence with New Georgia Café

Updated Category News Views 163

Café Culture Meets Expansion Chase You ever sip a cup of coffee and hear the rustle of opportunity in the steam? That's what's brewing at Paris Baguette with their new opening in Peachtree Corners, Georgia. This isn't just another café setting up shop; it's part of a larger scheme—expanding their sweet slice of the global market pie. Paris Baguette's Georgia Gamble...

Continue Reading
Ranger and Smith Unveil Tea-Infused Chocolate Bar

Updated Category News Views 88

Fresh Collaborations in Portland's Culinary Scene Ah, the sweet crossover in Portland's food scene is once again in the spotlight with a new entry that's sure to titillate taste buds. Ranger Chocolate Co. and Steven Smith Teamaker are at it again, rolling out a delectable creation that merges the poetic elegance of tea with the indulgent richness of chocolate. Welcome,...

Continue Reading
Intel Hit by Securities Law Suit Amid PC Market Struggles

Updated Category News Views 100

Intel Faces the Music: Legal Battles Unfold So it seems Intel's got itself in a kettle of fish. The tech giant is being dragged into a courtroom dance, courtesy of a class action lawsuit led by DJS Law Group. Shareholders who snapped up Intel shares between July 23 and October 29, 2026, might be scratching their heads, wondering if they bought into a bit of a mirage. A...

Continue Reading
NVCA Refreshes Key Venture Legal Documents for 2026

Updated Category News Views 115

Keeping Pace with Evolving Venture Norms Change never lets up in the fast-paced world of venture capital, does it? Just when you think you've got the rules figured out, the game shifts. This time, it's the National Venture Capital Association (NVCA) shaking things up. They've given a facelift to seven of their model legal documents, a move that reshapes the legal...

Continue Reading

Top 5 Most Recently Viewed Articles

Lake Chelan Health Partners with Medline for Improved Care

Updated Category News Views 364

Lake Chelan Health's Collaboration with Medline In an exciting development, Lake Chelan Health, a critical access hospital located in Washington, has entered into a strategic Prime Vendor agreement with Medline, one of the leading suppliers of medical-surgical products. This partnership is set to elevate their supply chain resilience and enhance the availability of...

Continue Reading
Investors of Dow Inc. Urged to Join Class Action Lawsuit

Updated Category News Views 232

Invitation for Dow Inc. Investors Are you an investor in Dow Inc. (DOW)? If you have faced significant losses during a certain period, there is an opportunity for you to become involved in a class action lawsuit. This is especially important for those who acquired Dow securities from January 30, 2025 to July 23, 2025. Individuals who believe they are eligible are...

Continue Reading
Strategic Growth at Future Technologies with New Chairperson

Updated Category News Views 197

Future Technologies Ventures Welcomes New Leadership In a strategic move to enhance its operations, Future Technologies Venture, LLC recently appointed Mary Peterson as Chairperson of its Advisory Board. This significant addition comes after a recapitalization with Battle Investment Group, marking an exciting chapter for the company. Mary Peterson's Role in Future...

Continue Reading
Cineverse Brings Halloween Thrills with 31-Day SCREAMBOX Event

Updated Category News Views 180

Cineverse's 31 Days of Halloween Celebration Cineverse is gearing up for an exciting Halloween season with their unique event, 31 Days of Halloween, hosted on their SCREAMBOX streaming service. This initiative aims to deliver chilling thrills and engaging experiences tailored for horror enthusiasts around the globe. Featured Film Premiere: Bloodsuckers and the Grimoire...

Continue Reading
ParkerVision Prevails Against Qualcomm in U.S. Federal Court

Updated Category News Views 77

ParkerVision Achieves a Legal Milestone Against Qualcomm The legal battle between ParkerVision and Qualcomm has taken a notable turn, with ParkerVision recently securing a significant victory. The U.S. Court of Appeals for the Federal Circuit has delivered a favorable opinion, marking an important moment for ParkerVision as it strives to safeguard its intellectual...

Continue Reading